<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: Tissue microarrays allow the simultanous, rapid and standardized in-situ analysis of up to 1000 different tissue samples on a single glass slide </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the expression profil and the prognostic significance of CD24, p53 and p21 using a Non-Hodgkin-<z:hpo ids='HP_0002665'>Lymphoma</z:hpo> tissue microarray </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Over 600 well documented Non-Hodgkin-<z:hpo ids='HP_0002665'>Lymphomas</z:hpo>, consisting of 341 diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 86 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 81 <z:hpo ids='HP_0005550'>chronic lymphatic leukemias</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 51 primary mediastinal diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 26 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 8 lymphoplasmocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 8 T-cell-<z:hpo ids='HP_0002665'>lymphomas</z:hpo> NOS und 2 Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were brought into array format </plain></SENT>
<SENT sid="3" pm="."><plain>The expression of CD24, p53 and p21 was analysed semiquantitatively by immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>The immunophenotype p53+/p21- (Deltap53) was used as a surrogat for p53 gene mutations </plain></SENT>
<SENT sid="5" pm="."><plain>The expression profile was compared to clinical data and the overall survival in the subgroup of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: 91% of the analyzed Non-Hodgkin-<z:hpo ids='HP_0002665'>lymphomas</z:hpo> (473 of 522 cases) showed CD24 positivity </plain></SENT>
<SENT sid="7" pm="."><plain>CD24 Expression was not associated with survival </plain></SENT>
<SENT sid="8" pm="."><plain>Deltap53 was found in thirteen percent of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (70 of 539 cases), the subgroup of the diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> demonstrated the highest Deltap53 (21%) </plain></SENT>
<SENT sid="9" pm="."><plain>In a multivariate cox regression analysis, a high international prognostic index and Deltap53 were independent markers of bad survival </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The <z:chebi fb="39" ids="18139,53050">TMA</z:chebi>-technology allows also in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> research the simultanous, cost-effective and standardized analysis of large patient cohorts </plain></SENT>
<SENT sid="11" pm="."><plain>Deltap53 revealed as an independent negative prognostic factor in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>It can easily be determined in daily routine practice </plain></SENT>
</text></document>